Investigational drug · Phase 3
Seralutinib
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Pulmonary Arterial Hypertension.
Phase 3Last checked: Nov 20, 2026Latest source record: Oct 13, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
1 still active
All registered trials
5
Any phase or sponsor naming "Seralutinib"
First trial start
2023
Dec 28, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Seralutinib", any sponsor or status.
Conditions studied
As listed on its trial records.
- Pulmonary Arterial Hypertension
Approved drugs for the same conditions: High blood pressure (hypertension) · Pulmonary arterial hypertension · Cardiovascular and metabolic · Respiratory
Largest trials
Live from ClinicalTrials.gov: studies naming "Seralutinib" as an intervention, largest first.
- Efficacy and Safety of Seralutinib in Adult Subjects With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)Pivotal-lookingSuspended
GB002, Inc.Industry
NCT07181382 · 480 participants (planned) · Start Feb 2026 · Primary completion Dec 2028
Drug: Placebo; Seralutinib · For: Pulmonary Hypertension Associated With Interstitial Lung Disease
Sites: Fresno, California; Albuquerque, New Mexico; Richmond, Virginia · 4 sites in all
- Efficacy and Safety of Seralutinib in Adult Subjects With PAH (PROSERA)Pivotal-lookingCompleted
GB002, Inc.Industry
NCT05934526 · 390 participants · Start Dec 28, 2023 · Primary completion Nov 27, 2025
Drug: Placebo; Seralutinib · For: Pulmonary Arterial Hypertension
Sites: Birmingham, Alabama; Fresno, California; Los Angeles, California · 166 sites in all
- Open-label Extension Study of Seralutinib in Adult Subjects With PAH (PROSERA-EXT)Pivotal-lookingRecruiting
Gossamer Bio USA, Inc.Industry
NCT06274801 · 330 participants (planned) · Start Sep 3, 2024 · Primary completion Dec 2026
Drug: Seralutinib · For: Pulmonary Arterial Hypertension
Sites: Fresno, California; Los Angeles, California; Sacramento, California · 120 sites in all
GB002, Inc., a wholly owned subsidiary of Gossamer Bio, Inc.Industry
NCT04456998 · 86 participants · Start Nov 12, 2020 · Primary completion Oct 17, 2022
Drug: GB002 (seralutinib); Placebo · For: Pulmonary Artery Hypertension
Sites: Phoenix, Arizona; Los Angeles, California; Sacramento, California · 63 sites in all
- Open-label Extension Study of GB002 in Adult Subjects With Pulmonary Arterial Hypertension (PAH)Terminated
Gossamer Bio USA, Inc.Industry
NCT04816604 · 74 participants · Start Apr 5, 2021 · Primary completion Sep 9, 2026
Drug: GB002 (seralutinib) · For: Pulmonary Arterial Hypertension
Sites: Sacramento, California; Santa Barbara, California; Jacksonville, Florida · 28 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- First-in-human safety and pharmacokinetic evaluation of seralutinib, an investigational inhaled tyrosine-protein kinase inhibitor for pulmonary hypertension.
Li J, Zisman LS, Cravets M, et al. · Pulm Pharmacol Ther 2026
- Circulating biomarker results from a phase 2 study of seralutinib in pulmonary arterial hypertension.
Osterhout R, Boucly A, Benza RL, et al. · Am J Respir Crit Care Med 2026
- Pulmonary arterial hypertension from a translational perspective: Bridging pathophysiology and treatment.
Yang T, Chung WJ · Chin Med J (Engl) 2026
- Clinical research on pulmonary hypertension from a 2025 perspective: a narrative review.
Bai Q, Liu H, Wang H, et al. · J Thorac Dis 2026
- Update on pulmonary hypertension.
Olschewski H · Respir Res 2026
- Seralutinib for the Treatment of Pulmonary Arterial Hypertension in Adults: TORREY Open-Label Extension Study.
Sitbon O, Sahay S, Escribano Subías P, et al. · Adv Ther 2025
Also in development for Pulmonary Arterial Hypertension
- INS1009Treprostinil PalmitilPhase 37 trials
Insmed Incorporated · Interstitial Lung Disease, Pulmonary Hypertension, Pulmonary Arterial Hypertension
- IKT-001Phase 32 trials
Inhibikase Therapeutics · Pulmonary Arterial Hypertension, Pulmonary Arterial Hypertension (PAH)
- RalinepagAPD811Phase 32 trials
United Therapeutics · PAH, Pulmonary Hypertension, Pulmonary Arterial Hypertension
- HS235Phase 22 trials
35Pharma Inc., a GSK company · Pulmonary Arterial Hypertension, Pulmonary Hypertension, Heart Failure With Preserved Ejection Fraction
- NS-863Phase 22 trials
NS Pharma, Inc. · Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD), Pulmonary Arterial Hypertension
- APL-9796Phase 21 trial
Apollo Therapeutics Ltd · Pulmonary Arterial Hypertension
- DIAG723Phase 21 trial
Diagonal Therapeutics, Inc. · Hereditary Hemorrhagic Telangiectasia, Pulmonary Arterial Hypertension
- PF-07868489Phase 21 trial
Pfizer · Pulmonary Arterial Hypertension
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.